The pyrimidine deoxyribonucleoside, thymidine, is converted enzymatically to the free pyrimidine, thymine, in a variety of tissues, including liver, spleen, and bone marrow (1) (2) (3) (4) . Little information is available concerning human leukocyte catabolism of thymidine, although it has been used extensively in isotopic form to study leukocyte DNA synthesis (5) (6) (7) (8) .
While investigating the influence of various leukocyte homogenates on the uptake of tritiated thymidine (H3TdR) by isolated leukocytes from patients with chronic myelocytic leukemia (CML), we obtained data that suggested the presence of thymidine phosphorylase activity. This report presents the evidence for activity of this enzyme in human leukocytes and the values obtained for this enzyme activity in different types of leukocytes. Methods
Leukocyte isolation. Whole blood was drawn from patients with various hematologic disorders and from normal volunteers. Leukocytes were isolated by a modification of the method of Fallon and associates (9) . Streptokinase-streptodornase was not used. The isolated cells were washed once with 10 ml of 5% glucose, resuspended in the same volume, and counted in an electronic cell counter.' The cells were then centrifuged for 15 minutes at 2,100 X g and resuspended in the appropriate solution at the desired concentration. Cells to be assayed for thymidine phosphorylase were resuspended in isotonic saline for counting. Aspirated bone marrow specimens were treated in a similar fashion. Lymph2 was obtained by cannulation of the thoracic duct of a patient with a malignancy who was being studied for circulating tumor cells. It was collected in heparin (1,000 U per 50 ml of lymph) on ice and cen-Leukocyte preparations. Homogenates for incubation with intact CML cells were made in a homogenizer 3 at 5,000 rpm for 15 minutes in the cold, with 108 to 109 leukocytes per milliliter of 0.1 M phosphate buffer, pH 7.2, and 0.25 g of glass beads (average diameter, 0.2 mm) per 10' cells. The mixture was centrifuged for 20 minutes at 37,000 X g and 4' C, and the supernatant fluid was refrigerated overnight and used the following day.
Supernatant solutions from leukocytes were prepared by incubating normal or CML cells, 10' per ml, in phosphate buffer for 2 hours at 370 C, and centrifuging at 37,000 X g. Homogenates of the residual cells were made as above in a concentration of 10' leukocytes per milliliter.
Homogenates for thymidine phosphorylase assay were prepared as above, with 1.25 X 10, cells per milliliter of 0.15 M Tris-HCl buffer, pH 7.1, and 0.5 g of glass beads. Assays were performed on the day of preparation.
CML cell uptake of H'TdR. Two X 10' freshly isolated CML cells in 0.2 ml of 5% glucose were added to 0.3 ml of autologous heparinized plasma (500 U of heparin per 25 ml blood), 1.2 ml of Robinson's salt mixture (10) , pH 7.4, supplemented with 100 mg glucose per 100 ml and 209 mg sodium bicarbonate per 100 ml, and 0.2 ml of the leukocyte homogenate being tested or 0.1 M phosphate buffer as a control. After incubation for 1 hour at 370 C in a screw-top vial, 1 ,uc of H'TdR (SA, 0.36 c per mmole)4 in 0.1 ml of isotonic saline was added and the incubation continued for an hour. In some experiments, hereafter referred to as "preincubation experiments," the H'TdR was incubated first with the leukocyte homogenate and Robinson's solution for an hour. The CML cells and plasma were then added and the incubation continued for another hour. All incubations were performed in duplicate. The incubations were terminated by placing the vials in ice, after which the contents were transferred quantitatively with 2 ml of isotonic saline to test tubes that were centrifuged at 1,400 X g for 10 minutes at 40 C. The cells were washed three times with saline, which was sufficient to remove 3 MSE homogenizer, Measuring and Scientific Equipment, Ltd., London, England. 4 Schwarz BioResearch, Inc., Orangeburg, N. Y. 267 extracellular radioactivity. They were then dissolved in 0.5 ml of 5% sodium hydroxide at 600 C for 15 minutes, and 0.1 ml of the resulting solution was added to 18 ml of a scintillation mixture, 70% toluene, 30% methanol containing 3 g of 2,5-diphenyloxazole (PPO) and 0.050 g of 1,4-bis-2-(4-methyl-5-phenyloxazolyl) benzene (dimethyl POPOP) per L. After 48 hours at -5°C, the samples were counted in duplicate in a liquid scintillation spectrometer. Quenching was found to be negligible with the use of internal standards.
In one experiment, the residual media from incubation were treated with 0.2 ml of 70% perchloric acid in the cold to precipitate protein and centrifuged at 2,100 X g for 10 minutes. The supernatant fluid was neutralized with 0.38 ml of 6 N potassium hydroxide and recentrifuged. Two-tenths ml of the resulting supernatant fluid was applied to Whatman 3 MM filter paper for descending chromatography.
Distribution of intracellular radioactivity. The method of Williams and Schilling (11) was used to separate the acid soluble fraction, protein, RNA, and DNA from cells incubated as described above with the following modifications: 1) Centrifugation was at 2,100 X g at 4°C for 10 minutes. 2) RNA was hydrolyzed by suspending the precipitated nucleic acid in 0.5 ml of 0.3 N sodium hydroxide and incubating 1 hour at 370 C. 3) DNA was precipitated by chilling and adding 0.5 ml of cold 0.5 N hydrochloric acid. 4) The protein residue and DNA were dissolved in 0.5 ml 0.5 N sodium hydroxide by heating at 800 C for 15 minutes. 5) Radioactivity was determined as above.
Incubation of H'TdR with cell-free leukocyte preparations. Mixtures were prepared with 1.2 ml of Robinson's solution, supplemented with glucose and sodium bicarbonate as above, 150 jug of thymidine, 1 ,uc of H'TdR, and 0.2 ml of either the supernatant solution from incubation of leukocytes in phosphate buffer or the homogenate prepared from the original cells. The mixtures were shaken gently at 37°C for 1 hour and the reaction stopped by boiling for 5 minutes. The leukocyte preparations were added at the time of boiling in the control tubes. After centrifugation at 2,100 X g for 10 minutes, 0.1 ml of each sample was chromatographed in several systems on Whatman 3 MM filter paper.
Paper chromatography. The solvents employed for descending chromatography were butanol, water, and ammonia (60: 30: 10) (12), ethyl acetate, water, and formic acid (60: 35: 5) (13) , and isobutyric acid, water, and ammonia (66: 33: 1) (14) .
Standards of thymine, thymidine, 5'-thymidine triphosphate (TTP), dihydrothymine (DHT),6 and 8i-ureidoisobutyric acid (BUIB) were chromatographed with the samples. BUIB was prepared from DHT and dilute alkali, and both compounds were identified by spraying the dried chromatogram with dilute alkali followed by p-dimethylaminobenzaldehyde (15 No attempt was made to purify the inhibitory factor extensively, but when prepared from normal leukocytes, it was found in the precipitate after 40%o saturation with ammonium sulfate. It was not dialyzable, and activity was lost after heating to 600 C for 30 minutes.
Several experiments suggested that less thymidine uptake by intact cells occurred with in- Thymine formation by leukocyte preparations. When the supernatant solution from incubation of CML or normal leukocytes in phosphate buffer or the homogenate from the residual cells was incubated with H3TdR and thymidine, a radioactive peak corresponding to the position of thymine was found when the incubation mixture was chromatographed (Table V) . No such peak was found when the leukocyte preparations were heated to 60°C before incubation. No evidence for DHT, BUIB, or thymine nucleotide formation was found in this cell-free system when other chromatographic systems were used. Although the preparations from the normal leukocytes seemed to have more converting activity than the CML preparations, no definite conclusion is possible since only one experiment of this type was performed.
Thymidine phosphorylase activity of peripheral leukocyte and bone marrow homogenates. A modification of the arsenolysis assay method of Friedkin and Roberts (3) was used to take advantage of the spontaneous decomposition of the reaction product, deoxyribose-1-arsenate. Under the conditions used, the increase in OD300 in Figure 3 ). The CML homogenates were higher than those from CLL and the acute leukemias (AL) (p < 0.001). CLL and AL homogenates did not differ significantly when compared in this fashion (p < 0.70).
When the data were expressed as enzyme activity per milligram of homogenate protein, i.e., specific activity, the normal homogenates were still significantly higher than CML (p < 0.01) and AL (p < 0.001). The the same type of leukemia. Two CML patients in remission and a patient with a leukemoid reaction had enzyme activities in or slightly above the normal range. The normal and CML bone marrow values were lower than the normal peripheral leukocyte values. The thoracic duct lymphocytes had very low levels of enzyme activity. Erythrocytes had no detectable activity and did not inhibit active leukocyte preparations.
Correlation of thymidine phosphorylase activity and inhibition of H3TdR uptake. Homogenates prepared identically in Tris buffer ( 1.25 x 108 cells per ml) from normal, CML, CLL, and acute myelocytic leukemia (AML) leukocytes were assayed simultaneously for thymidine phosphorylase activity and for their ability to inhibit H3TdR uptake by CML cells. Two incubation conditions were studied. There was good correlation between enzyme activity and inhibition of isotope uptake when the cells and homogenate were incu- bated together (Figure 4) . The normal homogenate was most active, followed by the CML, CLL, and AML homogenates in order. This relationship was also found in the preincubation experiments, except that the activity of the normal and CML homogenates appeared to be equal, since both caused virtual complete inhibition of H3TdR uptake. The AML homogenate, which had negligible enzyme activity, increased the uptake of the isotope by the CML cells. The last two concentrations correspond to the plasma levels after doses of the drug ranging from 15 to 100 mg per kg in man (23, 24) . At a concentration of 76 and 7.6 mg per L, hydroxyurea had no effect on thymidine phosphorylase activity and was additive with it in inhibiting H3TdR uptake by CML cells.
Phytohemagglutinin has growth-stimulating effects on leukocyte cultures (25) and has been reported to inhibit leukocyte alkaline phosphatase when thymidylic acid (TMP) is used as a substrate (26) . At a concentration corresponding to 0.4 ml of phytohemagglutinin9 per 10 ml of culture medium there was no effect on thymidine phosphorylase activity, and one-half this concentration had no effect on H3TdR uptake by CML cells. Discussion These experiments have demonstrated inhibition of H3TdR uptake into CML cells by a nondialyzable, heat-labile leukocyte factor that was more effective as phosphate concentration was increased and when it was preincubated with H3TdR before addition of the cells. When the cells alone were incubated with H3TdR, the residual radioactivity of the medium suggested the formation of thymine, DHT, and possibly BUIB. The inhibitory factor increased the amount of these compounds found in the medium while decreasing the amount of residual thymidine. Similar compounds have recently been found in stu(l-ies of H3TdR uptake by plant tissues (27) . Normal and CML leukocytes were capable of elaborating this factor when incubated in phosphate buffer.
Partial purification of the inhibitory factor showed that it was precipitable at 40%o saturation with ammonium sulfate, as is human spleen (4) and horse liver (3) thymidine phosphorylase. It also inhibited CML cell uptake of tritiated deoxyuridine, which is a substrate for thymidine phosphorylase in other species (3). Good correlation was found between thymidine phosphorylase activity and the ability to inhibit H3TdR uptake into CML cells. It may be concluded that this inhibitory effect is due to thymidine phosphorylase.
Craddock (28) reported that normal intact human granulocytes or homogenates had a greater inhibitory effect than leukemic cells on labeling of dog thoracic duct lymphocytes with H3TdR. Dog lymphocytes and erythrocytes had little effect. Because of the studies reported above, his results may be attributed, at least in part, to different amounts of thymidine phosphorylase in the cells tested.
An enzyme catalyzing the conversion of thymidine to thymine was first described by Deutsch and Laser (1) in 1929, who found activity in beef bone marrow and rabbit leukocytes. Klein (2) in 1935 confirmed these findings and found similar activity in beef kidney, spleen, lung, lymph nodes, and other tissues. The enzyme was activated by arsenate and phosphate. Friedkin and Roberts (3) purified thymidine phosphorylase from horse liver and described its kinetics and substrate specificity. They also found activity in human bone marrow. Zimmerman (4) has recently surveyed enzyme activity in many human tissues, including spleen and various tumors. There have been no reports of thymidine phosphorylase activity in human peripheral leukocytes. A purine nucleoside phosphorylase is present in guinea pig leukocytes (29) .
Many investigators have demonstrated differences in enzyme levels, particularly those concerned with DNA metabolism, between rapidly growing and stable tissues. Thymidine kinase and thymidylate kinase activities increase in regenerating rat liver with a simultaneous decrease in the activities of enzymes concerned with pyrimidine catabolism (30, 31) . Potter, Pitot, and Ono (32) have shown generally decreased pyrimidine catabolic activity in rat hepatomas. Wheeler, Alexander, and co-workers (33-35) have obtained similar results in studies of purine metabolism in animal tumors. Smith, Baker, and Sullivan (36) have shown increased levels of enzymes regulating de novo pyrimidine synthesis in CML leukocytes, but to our knowledge, enzymes involved in pyrimidine catabolism in leukocytes have not been studied. A simplified version of the current concept of thymidine catabolism is shown in Figure 5 .
The physiologic role of thymidine phosphorylase has not been defined. The equilibrium of the thymidine-thymine reaction is favorable to nucleoside synthesis in cell-free systems (37 Since the value obtained for the enzyme activity of thoracic duct lymphocytes was low, the enzyme in normal peripheral leukocytes would seem to be located primarily in the granulocytes.
The data in this report suggest the further conversion of thymine to additional products, probably DHT and, perhaps, BUIB by intact CML cells. The failure to find evidence for formation of these compounds in the cell-free system may be due to the absence or inactivation of the necessary enzymes in the homogenates used or to the lack of TPNH. This pyridine nucleotide has been shown to be a required cofactor in the conversion of thymine to DHT in other tissues (40) .
Certain considerations have been pointed out in the interpretation of experiments using H3TdR as a DNA label. These include radiation effects (41), reutilization (42) , and low thymidine kinase activity (43) . To these should be added the fact that different cell populations contain different levels of thymidine phosphorylase activity, which may profoundly affect their uptake of H3TdR. In addition, one cell population may influence the uptake of H3TdR by another through elaboration of the enzyme into the immediate environment. Summary 1) Leukocyte homogenates inhibit the uptake of tritiated thymidine by chronic myelocytic leukemia cells. The degree of inhibition correlates with the level of thymidine phosphorylase activity.
2) Thymidine phosphorylase activity is also found in the medium after intact leukocytes are incubated in phosphate buffer.
3) Normal leukocytes contain significantly higher levels of thymidine phosphorylase activity than leukemic leukocytes. Leukocytes from patients with leukemia in remission had higher enzyme levels than those from patients in relapse.
4) In addition to demonstrating thymidine phosphorylase activity converting thymidine to thymine, chronic myelocytic leukemia cells in vitro can reduce thymine to a compound corresponding chromatographically to dihydrothymine, or 18-ureidoisobutyric acid, or both. 5) Low thymidine phosphorylase activity may be a function of cellular immaturity and capacity for DNA synthesis, rather than a characteristic of leukemia per se.
